Nano-Enabled Drug Candidate Receives Initial FDA Approval
Calando Pharmaceuticals recently announced that the FDA has approved its investigational new drug application for its anti-cancer compound, CALAA-01. The companyâ€™s drug is a targeted nanoparticle delivered via its proprietary polymer delivery system. The FDA has approved a Phase I trial that will be conducted at the UCLA Jonsson Cancer Center (UCLA) in Los Angeles, California, and the South Texas Accelerated Research Therapeutics (START) clinic in San Antonio, Texas. The clinical trials will be co-led by Dr. Antoni Ribas (UCLA) and Dr. Anthony Tolcher (START).